Biosensia developed RapiPlex, a point-of-care diagnosis system based on proprietary technologies capable of producing quantitative and qualitative laboratory quality test results.
Biosensia merged with Kypha in 2018, a USA based in-vitro diagnostics company, to co-develop immune and inflammation assays on the Biosensia point-of-care RapiPlex platform.
Copyright © 2024 Seroba. All rights reserved.
Legal | Privacy | Sustainability
Biosensia merged with Kypha in 2018, a USA based in-vitro diagnostics company, to co-develop immune and inflammation assays on the Biosensia point-of-care RapiPlex platform.
Copyright © 2024 Seroba. All rights reserved.
Legal | Privacy | Sustainability
Total raised: $1.56M
Investors 1
| Date | Name | Website |
| - | Seroba Lif... | seroba-lif... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.12.2011 | - | $1.56M | - |
Mentions in press and media 1
| Date | Title | Description |
| 19.12.2011 | Biosensia Raises €1.2M in Funding | Biosensia, a Dublin, Ireland-based point of care diagnostics company, recently raised €1.2m in funding. The round was led by ACT Venture Capital, through its AIB Start-up Accelerator Fund, with participation from existing investors Seroba B... |